Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with locally advanced or metastatic UC before receiving Avelumab 1L maintenance therapy.~2. Started treatment with avelumab for locally advanced or metastatic UC from 24 Feb 2021 (regulatory approval date) to 30 Nov 2021.~3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~(1) Written consent is not required for patients who were transferred to a hospital, and registration with verbal consent is acceptable.~(2) Opt-out enrollment is allowed for patients who have already died. 4)Deceased patients are also required to meet the inclusion criteria 1)-2).~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma (Type: None): Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma who were treated with avelumab as first-line maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).